Scholarlink

Background <p>Predicting recurrence in meningioma patients is vital for improving long-term outcomes and tailoring personalized treatment strategies. While traditional diagnostic methods have advanced, accurately forecasting recurrence remains a persistent and critical challenge. This study explores the cutting-edge application of artificial intelligence (AI)-based models, which seamlessly integrate clinical, radiological, and pathological data, offering a transformative approach to enhancing the reliability and precision of recurrence prediction.</p> Methods <p>Eligible studies were identified through a comprehensive search of the Web of Science, Scopus, PubMed, and Embase databases. Extracted and synthesized metrics for analysis included accuracy, sensitivity, specificity, precision, F1 score, and area under the curve (AUC). Out of 2,971 studies screened, six met the inclusion criteria for systematic review, and three were included in the meta-analysis.</p> Results <p>The pooled sensitivity and specificity of AI models were 0.86 [95% CI: 0.78–0.92] and 0.86 [95% CI: 0.81–0.90], respectively. The positive diagnostic likelihood ratio (DLR) was 6.33 [95% CI: 4.42–9.08], and the negative DLR was 0.16 [95% CI: 0.09–0.27]. The diagnostic odds ratio (DOR) was estimated at 40.11 [95% CI: 19.30–83.37], with a diagnostic score of 3.69 [95% CI: 2.96–4.42] and a pooled area under the curve (AUC) of 0.93 [95% CI: 0.90–0.95]. Subgroup analysis showed comparable sensitivity (RF: 0.88; LR: 0.84) and specificity (RF: 0.84; LR: 0.84) with no significant heterogeneity (I² = 0%).</p> Conclusions <p>These findings highlight the potential of AI-based models to predict meningioma recurrence, offer superior diagnostic accuracy, and aid clinical decision-making. Integrating clinical, radiological, and pathological data through AI-driven models demonstrates substantial promise in enhancing the reliability and efficiency of recurrence forecasting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Machine learning-based models and radiomics: can they be reliable predictors for meningioma recurrence? A systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年8月27日

查看全文
  • Behnaz Niroomand,
  • Ibrahim Mohammadzadeh,
  • Bardia Hajikarimloo,
  • Mohammad Amin Habibi,
  • Shahin Mohammadzadeh,
  • Amir Mohammad Bahri,
  • Mohammad Hassan Bagheri,
  • Abdulrahman Albakr,
  • Brij S. Karmur,
  • Hamid Borghei-Razavi

摘要

Background

Predicting recurrence in meningioma patients is vital for improving long-term outcomes and tailoring personalized treatment strategies. While traditional diagnostic methods have advanced, accurately forecasting recurrence remains a persistent and critical challenge. This study explores the cutting-edge application of artificial intelligence (AI)-based models, which seamlessly integrate clinical, radiological, and pathological data, offering a transformative approach to enhancing the reliability and precision of recurrence prediction.

Methods

Eligible studies were identified through a comprehensive search of the Web of Science, Scopus, PubMed, and Embase databases. Extracted and synthesized metrics for analysis included accuracy, sensitivity, specificity, precision, F1 score, and area under the curve (AUC). Out of 2,971 studies screened, six met the inclusion criteria for systematic review, and three were included in the meta-analysis.

Results

The pooled sensitivity and specificity of AI models were 0.86 [95% CI: 0.78–0.92] and 0.86 [95% CI: 0.81–0.90], respectively. The positive diagnostic likelihood ratio (DLR) was 6.33 [95% CI: 4.42–9.08], and the negative DLR was 0.16 [95% CI: 0.09–0.27]. The diagnostic odds ratio (DOR) was estimated at 40.11 [95% CI: 19.30–83.37], with a diagnostic score of 3.69 [95% CI: 2.96–4.42] and a pooled area under the curve (AUC) of 0.93 [95% CI: 0.90–0.95]. Subgroup analysis showed comparable sensitivity (RF: 0.88; LR: 0.84) and specificity (RF: 0.84; LR: 0.84) with no significant heterogeneity (I² = 0%).

Conclusions

These findings highlight the potential of AI-based models to predict meningioma recurrence, offer superior diagnostic accuracy, and aid clinical decision-making. Integrating clinical, radiological, and pathological data through AI-driven models demonstrates substantial promise in enhancing the reliability and efficiency of recurrence forecasting.